Economic Times
Swiss AI drug trial startup receives funding from Spotify-backer Creandum
An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
By Economic Times
Excerpt shared by Lazyfounder
·Excerpt
Synopsis
An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
AgenciesZURICH: Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer of Spotify…
Courtesy
This story was originally published by Economic Times. All rights belong to the original publisher.
Read the original on economictimes.indiatimes.com ↗